Document Detail

Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension.
MedLine Citation:
PMID:  10679495     Owner:  NLM     Status:  MEDLINE    
To examine the long-term effects of weight loss and dietary sodium reduction on the incidence of hypertension, we studied 181 men and women who participated in the Trials of Hypertension Prevention, phase 1, in Baltimore, Md. At baseline (1987 to 1988), subjects were 30 to 54 years old and had a diastolic blood pressure (BP) of 80 to 89 mm Hg and systolic BP <160 mm Hg. They were randomly assigned to one of two 18-month lifestyle modification interventions aimed at either weight loss or dietary sodium reduction or to a usual care control group. At the posttrial follow-up (1994 to 1995), BP was measured by blinded observers who used a random-zero sphygmomanometer. Incident hypertension was defined as systolic BP > or =160 mm Hg and/or diastolic BP > or =90 mm Hg and/or treatment with antihypertensive medication during follow-up. Body weight and urinary sodium were not significantly different among the groups at the posttrial follow-up. After 7 years of follow-up, the incidence of hypertension was 18.9% in the weight loss group and 40.5% in its control group and 22.4% in the sodium reduction group and 32.9% in its control group. In logistic regression analysis adjusted for baseline age, gender, race, physical activity, alcohol consumption, education, body weight, systolic BP, and urinary sodium excretion, the odds of hypertension was reduced by 77% (odds ratio 0.23; 95% confidence interval 0.07 to 0.76; P=0.02) in the weight loss group and by 35% (odds ratio 0.65; 95% confidence interval 0.25 to 1.69; P=0.37) in the sodium reduction group compared with their control groups. These results indicate that lifestyle modification such as weight loss may be effective in long-term primary prevention of hypertension.
J He; P K Whelton; L J Appel; J Charleston; M J Klag
Related Documents :
3125005 - Effect of cardiopulmonary resuscitation compression rate on end-tidal carbon dioxide co...
22322195 - Effects of isometric handgrip training on blood pressure (resting and 24 h ambulatory) ...
18716365 - Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a...
6278905 - Prediction of sustained antihypertensive efficacy of chronic captopril therapy: relatio...
8173695 - Increased urinary c-peptide and albumin excretion in juvenile borderline hypertensives.
1897475 - Eggs enriched in omega-3 fatty acids and alterations in lipid concentrations in plasma ...
Publication Detail:
Type:  Clinical Trial; Clinical Trial, Phase I; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Hypertension     Volume:  35     ISSN:  1524-4563     ISO Abbreviation:  Hypertension     Publication Date:  2000 Feb 
Date Detail:
Created Date:  2000-03-02     Completed Date:  2000-03-02     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  544-9     Citation Subset:  IM    
Department of Epidemiology, the Tulane University School of Public Health and Tropical Medicine, New Orleans, LA 70112-2699, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure
Body Weight
Dietary Supplements
Follow-Up Studies
Hypertension / epidemiology,  prevention & control*
Middle Aged
Single-Blind Method
Sodium / urine
Sodium, Dietary / administration & dosage*
Stress, Psychological / prevention & control
Time Factors
Treatment Outcome
United States / epidemiology
Weight Loss*
Grant Support
Reg. No./Substance:
0/Sodium, Dietary; 7440-23-5/Sodium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC ...
Next Document:  Regulation of sodium balance and blood pressure by the AT(1A) receptor for angiotensin II.